▎药明康德内容团队编辑今日，阿斯利康（AstraZeneca）公司公布了在研口服GLP-1疗法AZD5004，在患有2型糖尿病的肥胖患者中进行的1期临床试验的最新结果。数据显示，这款在研疗法在治疗4周后将患者体重减轻5.8%，并且改善患者的血糖指标。

基于优秀的循证医学证据，2024年，改善全球肾脏病预后组织（KDIGO）发布的CKD临床管理指南推荐SGLT2i作为CKD中的一线治疗药物（图3） [13] ...

慢性肾脏病（CKD）是临床常见疾病，我国 CKD 患者高达 1.32 亿[1]。一旦疾病进展至终末期肾脏病（ESKD），患者需进行肾脏替代治疗（包括血液透析、腹膜透析或肾移植等）以维持生命。 2024 年 8 月 1～4 ...

SAN DIEGO — Dapagliflozin provides significant benefits in the treatment of chronic kidney disease (CKD) even when initiated in patients with the most severe stages of the disease who are ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

At the second Appraisal Committee meeting, the Committee concluded that it was unable to decide on the most plausible ICERs, or to make a recommendation on dapagliflozin. This was due to a number of ...

A new study published in the journal of Arthritis & Rheumatology showed that interstitial lung disease (ILD) can occur in ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

2024年10月1日，北京大学第三医院内分泌科洪天配教授/魏蕊研究员团队在内分泌代谢专业传统优秀期刊《代谢》（Metabolism ...

Hypertension affects 1 in 8 adults aged between 20 and 40 years. The prevalence of hypertension among adults in India is ...

ProKidney's REACT® therapy shows kidney function stabilization. Find out why PROK stock is risky due to cash issues and ...